170 related articles for article (PubMed ID: 20512572)
1. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
[TBL] [Abstract][Full Text] [Related]
2. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
[TBL] [Abstract][Full Text] [Related]
3. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
[TBL] [Abstract][Full Text] [Related]
5. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
6. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
Ceci F; Castellucci P; Graziani T; Schiavina R; Renzi R; Borghesi M; Di Tullio P; Brunocilla E; Ardizzoni A; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):84-91. PubMed ID: 26323576
[TBL] [Abstract][Full Text] [Related]
7. Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.
Oyama N; Hasegawa Y; Kiyono Y; Kobayashi M; Fujibayashi Y; Ponde DE; Dence C; Welch MJ; Yokoyama O
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):81-9. PubMed ID: 20878403
[TBL] [Abstract][Full Text] [Related]
8. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
Müller SA; Holzapfel K; Seidl C; Treiber U; Krause BJ; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1434-42. PubMed ID: 19352653
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of [
Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
Challapalli A; Barwick T; Tomasi G; O' Doherty M; Contractor K; Stewart S; Al-Nahhas A; Behan K; Coombes C; Aboagye EO; Mangar S
Nucl Med Commun; 2014 Jan; 35(1):20-9. PubMed ID: 24201549
[TBL] [Abstract][Full Text] [Related]
13. [11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.
Schwarzenböck SM; Knieling A; Souvatzoglou M; Kurth J; Steiger K; Eiber M; Esposito I; Retz M; Kübler H; Gschwend JE; Schwaiger M; Krause BJ; Thalgott M
Oncotarget; 2016 Sep; 7(39):63747-63757. PubMed ID: 27572317
[TBL] [Abstract][Full Text] [Related]
14. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
15. Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with
Jadvar H; Park R; Vorobyova I; Chen K
Acad Radiol; 2023 Aug; 30(8):1721-1726. PubMed ID: 36184379
[TBL] [Abstract][Full Text] [Related]
16. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of
Piert M; Shao X; Raffel D; Davenport MS; Montgomery J; Kunju LP; Hockley BG; Siddiqui J; Scott PJH; Chinnaiyan AM; Rajendiran T
J Nucl Med; 2017 Aug; 58(8):1216-1223. PubMed ID: 28302759
[TBL] [Abstract][Full Text] [Related]
20. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
